# Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

> **NCT01445509** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01445509
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-29
- **Primary completion:** 2017-12-18
- **Final completion:** 2018-09-20
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01445509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01445509, "Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01445509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*